DA
IBB icon

Dover Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Dover Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Buy
2,173
+56
+3% +$9.63K 0.15% 117
2026
Q1 		$357K Sell
2,117
-56
-3% -$9.58K 0.15% 122
2025
Q4 		$367K Sell
2,173
-28
-1% -$4.55K 0.14% 125
2025
Q3 		$318K Sell
2,201
-21
-0.9% -$2.87K 0.13% 130
2025
Q2 		$281K Sell
2,222
-39
-2% -$4.79K 0.12% 140
2025
Q1 		$289K Sell
2,261
-357
-14% -$48.4K 0.13% 138
2024
Q4 		$346K Hold
2,618
– – 0.2% 99
2024
Q3 		$381K Hold
2,618
– – 0.22% 99
2024
Q2 		$359K Sell
2,618
-168
-6% -$22.4K 0.22% 98
2024
Q1 		$382K Buy
+2,786
New +$380K 0.26% 89
2023
Q4 		– Sell
-2,531
Closed -$310K – 89
2023
Q3 		$310K Hold
2,531
– – 0.31% 85
2023
Q2 		$321K Hold
2,531
– – 0.29% 81
2023
Q1 		$327K Hold
2,531
– – 0.31% 79
2022
Q4 		$332K Buy
+2,531
New +$327K 0.36% 75

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Dover Advisors's IBB Position: Q2 2026 in Review

Dover Advisors increased its iShares Biotechnology ETF (IBB) stake by 2.6% in Q2 2026, buying an estimated $9.63K and bringing the position to 2,173 shares worth $367K. The position accounts for 0.15% of the portfolio, ranked #117.

Dover Advisors first reported a position in IBB in Q4 2022 and has held it in 14 quarters since. The position peaked at $382K in Q1 2024. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Dover Advisors held 2,173 shares of iShares Biotechnology ETF worth $367K as of Q2 2026.
  • Dover Advisors bought 56 iShares Biotechnology ETF shares in Q2 2026, an estimated $9.63K.
  • iShares Biotechnology ETF made up 0.15% of Dover Advisors's portfolio in Q2 2026, its #117 holding.
  • Dover Advisors first reported a position in iShares Biotechnology ETF in Q4 2022 and has held it in 14 quarters since.
  • Dover Advisors's iShares Biotechnology ETF position peaked at $382K in Q1 2024.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Dover Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.